FlexCare Clinical Research, LLC (FlexCare) announced formation of the company, a clinical service provider focused on providing study visits in the home or alternate site settings via a network of clinicians.
FlexCare was created to meet demand from the biopharmaceutical industry to accelerate clinical trials and streamline study processes. Traditionally, clinical trials are conducted at investigative sites such as hospitals or clinics, where subjects are required to travel for protocol-related tests and assessments throughout the duration of the study. Consequently, for decades, subject recruitment and retention have become challenges in the timely completion of clinical trials. FlexCare’s service model is designed to take the study to the subject, where protocol activities can be conducted in their home or at other alternate locations. FlexCare’s services also hope to benefit pediatric or geriatric subjects, students and working adults who find participation in traditional studies inconvenient.
FlexCare centrally manages study visits that are conducted by its network of clinicians. Services offered by FlexCare include study drug administration, blood draws and other biologic sample collections, clinical assessments, questionnaires and training at the subject’s home or other convenient location.
With the company’s launch, Gail Adinamis was named to the role of chief executive officer. Concurrent with Adinamis’ appointment, Dr. Gizelle Baker was named chief operating officer and Dr. Debbie Wilkerson, chief scientific officer.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.